Sikorska, B., & Liberski, P. P. (2012). Human prion diseases: from Kuru to variant Creutzfeldt-Jakob disease. Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease, 457-496.

Pan, Keh-Ming. (1993). Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proceedings of the National Academy of Sciences, 90(23): 10962-10966.

Dobson, C.M. (2001). The structural basis of protein folding and its links with human disease. Philosophical Transactions of the Royal Society of London (Biological Sciences), 356 (1406): 133-45.

Mead, Simon. (2022). Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: evaluation of a first-in-human treatment programme. The Lancet Neurology, 21(4): 342-354.

Qin, K., O'Donnell, M., & Zhao, R. Y. (2006). Doppel: more rival than double to prion. Neuroscience, 141(1), 1-8.

Skillbäck, T., Rosén, C., Asztely, F., et al. (2014). Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. JAMA neurology, 71(4): 476-483.

Mizrahi, M., Friedman-Levi, Y., Larush, L., et al. (2014). Pomegranate seed oil nanoemulsions for the prevention and treatment of neurodegenerative diseases: the case of genetic CJD. Nanomedicine: Nanotechnology, Biology and Medicine, 10(6): 1353-1363.

Uttara, B., Singh, A. V., Zamboni, P., et al. (2009). Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Current neuropharmacology, 7(1): 65-74.

Haider, L., Fischer, M. T., Frischer, J. M., et al. (2011). Oxidative damage in multiple sclerosis lesions. Brain, 134(7): 1914-1924.

Freixes, M., Rodriguez, A., Dalfo, E., et al. (2006). Oxidation, glycoxidation, lipoxidation, nitration, and responses to oxidative stress in the cerebral cortex in Creutzfeldt–Jakob disease. Neurobiology of Aging, 27(12): 1807-1815.

Lu, D., Giles, K., Li, Z., et al. (2013). Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice. Journal of Pharmacology and Experimental Therapeutics, 347(2), 325-338.